On March 1, Jiangxi Synergy Pharmaceutical Co.Ltd(300636) announced that the company recently received a patent certificate issued by the U.S. patent and Trademark Office, which is a new preparation method of clenbuterol.
Clenbuterol is the first new molecular solid drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of atopic dermatitis in recent 15 years. It is used for the treatment of moderate and severe eczema in infants and adults aged 3 months or more. It has good efficacy and safety, and has good long-term safety and tolerance.
Compared with the prior art, the preparation method of the invention has the advantages of mild reaction conditions, high yield, good product quality and low production cost, and is especially suitable for industrial production.
The announcement said that the acquisition of the above invention patents will not have a significant impact on the company’s recent production and operation, but it is conducive to give full play to the company’s technical advantages of independent intellectual property rights and improve the intellectual property protection system, so as to enhance the company’s core competitiveness, especially conducive to the expansion of the company’s overseas market and play a positive role in the future production and operation.
